Skip to content
Medical Health Aged Care

Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide

Hims & Hers 5 mins read

Pilot becomes Hims, bringing innovative, personalised care to help Australian men manage sexual health, weight loss, and hair loss


SYDNEY--BUSINESS WIRE--

Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platform to men nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831313760/en/

The entry follows Hims & Hers' acquisition of Eucalyptus earlier this year and begins with the rebrand of Pilot, Eucalyptus' men's health platform. Effective today, Pilot becomes Hims. Patients will maintain the treatment plans and provider relationships they rely on, now backed by a platform used and loved by millions of men worldwide.

"For Australian men, digital care isn't just about convenience. It's about getting proactive help with the health issues that matter most to them, instead of waiting until it's unavoidable," said Gus Wood, General Manager of Australia at Hims & Hers. "Pilot has spent years earning that trust in Australia. Now we're building on that foundation with the leading global platform that sets the standard for men's health worldwide, so men can take charge of their health in the way that works for them, no matter where they live."

The stakes are highest outside major cities. Nearly 30% of Australians live in regional and rural Australia, where distance from a GP or specialist can impact whether care happens at all. Where Pilot's care team was previously available 12 hours a day, Hims' in Australia extends that to 24/7 access, pairing proactive, comprehensive treatment with a Care Team patients can reach any hour, making quality care seamless and straightforward.

"As a practising GP, I've seen how often men wait too long to act on something that was manageable if caught early," said Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, Chief Medical Officer of Hims Australia. "This launch unites clinical rigour and convenience. Every treatment plan is grounded in the same evidence-based standards I'd want for my own patients, just delivered in a way that fits into a man's life instead of asking him to work around it. That's how we actually move the needle on men's health outcomes here, not just access to it."

Patients will keep what they valued most from Pilot – Australian providers, local support, and continuity of care – while gaining access to a wider range of personalised care options built specifically for men's health. The launch also introduces combinations of care that bring together treatments that some patients previously received separately, including for premature ejaculation and cholesterol management. Patients will also gain access to new clinical pathways across multiple treatments and innovative formulations.

Serving Australian patients well starts with local leadership and clinical expertise. Tim Doyle, former CEO of Eucalyptus and now Hims & Hers Senior Vice President of International, will oversee the Australian market alongside Gus Wood, General Manager of Australia. Dr. Matt Vickers, FRACGP, MBBS, BMedSci, AICGG, will serve as Chief Medical Officer of Hims Australia, ensuring care is grounded in local clinical standards from day one.

About Hims & Hers Health, Inc.

Hims & Hers is the leading global health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the Company provides access to personalised care designed for results. For more information, please visit hims.com.au.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by the use of forward-looking terminology, including the words “anticipates,” “expects,” “intends,” “plans,” “decides,” “may,” “will,” “likely,” “potential,” “future,” “over time,” “coming,” “hope,” or “should,” or, in each case, their negative or other variations or comparable terminology. There can be no assurance that actual results will not materially differ from expectations. Such statements include, but are not limited to, statements regarding Hims & Hers' expansion into Australia, our long-term financial targets, revenue expectations with respect to the Australian market, the transition from Pilot to Hims, including available offerings, and assumptions relating to the foregoing. These statements are based on management's current expectations, but actual results may differ materially due to various factors.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, the forward-looking statements contained in this communication are based on our current expectations, assumptions and beliefs concerning future developments and their potential effects on us. Future developments affecting us may not be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, uncertainties relating to our ability to successfully integrate Eucalyptus and rebrand Eucalyptus’ brands; uncertainties relating to the transition from Pilot to Hims, including our ability to retain Pilot's existing patients and provider relationships through the transition; our ability to achieve anticipated revenue, growth, and other benefits from our expansion into Australia and other international markets; competitive dynamics in the Australian men's health market; our ability to achieve our long-term financial targets; risks associated with international operations; changes in the application, interpretation and enforcement of healthcare, consumer protection, privacy or other laws and regulations applicable to our business; and other factors described in the Risk Factors and other sections of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and other current and periodic reports we file from time to time with the Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The forward-looking statements contained in this communication are made only as of the date of this communication. We undertake no obligation (and expressly disclaim any obligation) to update or revise any forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.


Contact details:

Susan Cadrecha
[email protected]

Media

More from this category

  • Community, Medical Health Aged Care
  • 01/09/2026
  • 04:00
Astellas Pharma Australia

New treatment option on the PBS for locally advanced or metastatic bladder cancer

PADCEVTM in combination with pembrolizumab has been added to the Pharmaceutical Benefits Scheme for first-line (initial) treatment of locally advanced and metastatic bladder cancers1 In Australia, bladder cancer survival rates have gotten worse over the last 30–40 years, underscoring the need for new treatment options2,3 Chemotherapy has been the main treatment used when bladder cancer has spread4 SYDNEY, 1 September 2026 – Astellas Pharma Australia Pty Ltd today announced PADCEVTM (enfortumab vedotin) in combination with pembrolizumab has been listed on the Pharmaceutical Benefits Scheme (PBS) for first-line treatment of locally advanced or metastatic urothelial cancer.1 For the last 40 years,…

  • Contains:
  • Medical Health Aged Care
  • 01/09/2026
  • 01:45
Cancer Australia

New resources support Australians impacted by inherited cancer risk

Key Facts: Inherited Cancers Australia, supported by Cancer Australia, has launched nine educational resources and ten videos to help Australians affected by inherited cancer…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 01/09/2026
  • 00:00
Centre for Healthy Brain Ageing (CHeBA), UNSW Sydney

Documentary creators turn family’s dementia story into national call for research

UNDER EMBARGO UNTIL 1 SEPTEMBER 2026 Adelaide and Lucinda Miller join CHeBA’s Dollar for Dementia campaign ahead of SBS premiere during World Alzheimer’s Month…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.